Predicting progression-free survival from measurable residual disease in chronic lymphocytic leukemia.

ABSTRACT: Association between measurable residual disease (MRD) and survival outcomes in chronic lymphocytic leukemia (CLL) has often been reported. However, limited quantitative analyses over large datasets have been undertaken to establish the predictive power of MRD. Here, we provide a comprehensive assessment of published MRD data to explore the utility of MRD in the prediction of progression-free survival (PFS). We undertook two independent analyses, which leveraged available published data to address two complimentary questions. In the first, data from eight clinical trials was modeled via a meta-regression approach, showing that median PFS can be predicted from undetectable MRD rates at 3-6 months of post-treatment. The resulting model can be used to predict the probability of technical succe

SUBMITTER: Tettamanti FA 

PROVIDER: S-EPMC11335580 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature